Benzinga · Aug 12, 2026
BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target
BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.
MA
NASDAQ · MAZE
Maze Therapeutics, Inc.
Healthcare · Biotechnology
$29.43
Up+$0.50 (+1.73%)
Updated Aug 22, 2026, 9:01 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.9B
- P/E ratio
- -14.34
- Dividend yield
- 0.00%
- 52-week range
- $22.71 – $53.65
- Volume
- 280.59K
- Avg. volume
- 535.35K
Price performance
MAZE price history
1M range · 21 trading sessions · Daily adjusted prices
MAZE closed at $29.43 after 21 trading sessions, up 6.32% for the selected period.
- Last close
- $29.43
- Period change
- +6.32%
- Period low
- $26.92
- Period high
- $29.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $28.98 | $29.84 | $28.98 | $29.43 | 280.59K |
| Aug 20, 2026 | $29.53 | $29.99 | $28.46 | $28.93 | 247.67K |
| Aug 19, 2026 | $29.71 | $30.185 | $29.11 | $29.75 | 358.72K |
| Aug 18, 2026 | $27.89 | $29.195 | $27.00 | $29.13 | 649.53K |
| Aug 17, 2026 | $27.04 | $28.12 | $27.00 | $27.95 | 322.04K |
| Aug 14, 2026 | $27.47 | $27.61 | $26.85 | $27.18 | 230.65K |
| Aug 13, 2026 | $28.04 | $28.05 | $26.9701 | $27.665 | 383.35K |
| Aug 12, 2026 | $27.48 | $27.855 | $26.76 | $27.53 | 441.66K |
| Aug 11, 2026 | $27.30 | $28.365 | $26.53 | $27.31 | 379.88K |
| Aug 10, 2026 | $28.57 | $28.92 | $26.42 | $27.28 | 669.4K |
| Aug 7, 2026 | $28.95 | $29.00 | $27.445 | $28.65 | 480.73K |
| Aug 6, 2026 | $27.89 | $28.6499 | $26.16 | $28.53 | 231.11K |
| Aug 5, 2026 | $27.93 | $28.93 | $27.62 | $27.81 | 254.33K |
| Aug 4, 2026 | $27.50 | $28.345 | $27.245 | $27.61 | 367.36K |
| Aug 3, 2026 | $26.74 | $27.45 | $25.85 | $27.33 | 313.33K |
| Jul 31, 2026 | $27.41 | $27.705 | $25.85 | $26.92 | 335.59K |
| Jul 30, 2026 | $27.47 | $28.50 | $27.2875 | $27.63 | 335.02K |
| Jul 29, 2026 | $27.97 | $28.25 | $26.935 | $27.27 | 311.21K |
| Jul 28, 2026 | $28.85 | $29.35 | $27.58 | $27.88 | 383.13K |
| Jul 27, 2026 | $27.69 | $29.025 | $27.69 | $28.69 | 269.88K |
| Jul 24, 2026 | $28.01 | $28.12 | $27.39 | $27.68 | 166.03K |
Latest MAZE news
The latest Smart Investors Daily articles mentioning MAZE.
Stock researchCompany · Overview
MAZE research
Overview
Company profile and research snapshot.
Company profile
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $40.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | BTIG | Buy | — |
| Apr 14, 2026 | Truist Securities | Buy | — |
| Mar 31, 2026 | JP Morgan | Overweight | — |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 25, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from
SeekingAlpha · Jun 10, 2026
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Maze Therapeutics, Inc. (MAZE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 8:40 AM EDTCompany ParticipantsJason Coloma - CEO...
Benzinga · Mar 16, 2026
Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $58
Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raises the price target from $43 to $58.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
